Related Experiment Video

Updated: May 12, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

15.6K

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic

Yi Wang1, Guangchao Xu2,3, Hongwei Xia4

  • 1Department of Medical Aesthetics, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China.

The British Journal of Dermatology
|May 9, 2025
PubMed

Insights

Targeting mutant NRAS melanoma, a poor prognosis cancer, is advancing. New therapies focus on the NRAS-MAPK pathway, including MEK inhibitors and combination treatments, offering improved outcomes.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Mutant NRAS is a common driver in melanoma, associated with poor patient prognosis.
  • Current targeted treatment strategies for NRAS-mutant melanoma remain limited.
  • The NRAS-MAPK signaling pathway is crucial in melanoma carcinogenesis.

Purpose of the Study:

  • To systematically review recent advances in targeting mutant NRAS and its downstream effectors (RAF, MEK) in melanoma.
  • To explore combination therapies targeting the MAPK pathway with other modalities like immunotherapy.
  • To discuss current challenges and future strategies in NRAS-mutant melanoma targeted therapy.

Main Methods:

  • Literature review of recent clinical advancements and therapeutic strategies.
  • Systematic summary of direct NRAS targeting and downstream pathway inhibition.
  • Analysis of combination therapies including immunotherapy.

Main Results:

  • Significant clinical progress has been made in targeting the NRAS-MAPK pathway.
  • Novel therapies like MEK inhibitors (e.g., tunlametinib) and combination regimens (e.g., naporafenib/trametinib) show promise.
  • Combination strategies involving immunotherapy are emerging.

Conclusions:

  • Targeting the NRAS-MAPK pathway offers a promising therapeutic avenue for NRAS-mutant melanoma.
  • Addressing current issues and exploring novel countermeasures are essential for optimizing treatment outcomes.
  • Further research into combination therapies holds potential for improving survival in NRAS-mutant melanoma patients.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.2K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K